Effects of 9-cis Retinoic Acid on Neuroblastoma in Rats
Author Information
Author(s): Ponthan F, Kogner P, Bjellerup P, Klevenvall L, Hassan M
Primary Institution: Childhood Cancer Research Unit, Dept of Women's and Children's Health, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
Hypothesis
Does 9-cis retinoic acid have bioavailability and anti-tumor effects on human neuroblastoma xenografts in rats?
Conclusion
9-cis retinoic acid may have limited clinical significance for treating children with poor prognosis neuroblastoma.
Supporting Evidence
- 9-cis retinoic acid regulates growth and differentiation of neuroblastoma cells.
- The bioavailability of 9-cis RA in rats was found to be 11%.
- A lower dose of 9-cis RA (2 mg day−1) was non-toxic but ineffective against tumor growth.
- The toxic dose of 5 mg day−1 was divided into two doses of 2.5 mg p.o. twice daily, which showed no toxicity but limited effect.
Takeaway
The study looked at a medicine called 9-cis retinoic acid to see if it helps fight a type of cancer in kids, but it didn't work very well.
Methodology
The study investigated the bioavailability of 9-cis RA in rats and compared two different dose schedules.
Limitations
The study found that while a lower dose was non-toxic, it showed no significant effect on tumor growth.
Participant Demographics
Rats were used as the model for the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website